Houston, TX (January 26, 2006) CytoGenix, Inc. (CYGX.OB) announced today that it has filed a patent application titled Method of Making Nucleic Acid Therapeutics with the US Patent and Trademark Office.
Malcolm Skolnick, CytoGenix, Inc. CEO commented, "We will seek broad protection for the application of our synDNA process and its applications to DNA vaccines. This application incorporates the results of our successful animal tests of DNA vaccines against Smallpox, Hepatitis B, Influenza and HIV and extends the range of the protection of our technology."
About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA _expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission.
Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact: CytoGenix, Inc., Communications Director - Juan Ferreira, (800) 677-5707
